3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
80
Lymphoma
35
Lymphoma, Large-Cell, Anaplastic
26
Hematologic Diseases
21
Lymphoma, Non-Hodgkin
17
Recurrence
16
Lymphoma, T-Cell, Peripheral
14
Lymphoma, T-Cell, Cutaneous
13
Lymphoma, T-Cell
13
Lymphoma, Large B-Cell, Diffuse
10
Mycosis Fungoides
9
Sezary Syndrome
5
Neoplasms
5
Lymphoma, B-Cell
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphomatoid Papulosis
4
Lymphoma, Primary Cutaneous Anaplastic Large Cell
4
Lymphatic Diseases
4
Immunoblastic Lymphadenopathy
4
Enteropathy-Associated T-Cell Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Follicular
3
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphoma, Extranodal NK-T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Large Granular Lymphocytic
2
Interventions
pembrolizumab
5
Gemcitabine
1
Brentuximab Vedotin
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Brentuximab Vedotin
×
Lymphoid
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA